MX2019013683A - Una combinacion farmaceutica para el tratamiento de un cancer. - Google Patents
Una combinacion farmaceutica para el tratamiento de un cancer.Info
- Publication number
- MX2019013683A MX2019013683A MX2019013683A MX2019013683A MX2019013683A MX 2019013683 A MX2019013683 A MX 2019013683A MX 2019013683 A MX2019013683 A MX 2019013683A MX 2019013683 A MX2019013683 A MX 2019013683A MX 2019013683 A MX2019013683 A MX 2019013683A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- pharmaceutical combination
- simultaneous
- separate
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382282 | 2017-05-16 | ||
| PCT/EP2018/062554 WO2018210830A1 (en) | 2017-05-16 | 2018-05-15 | A pharmaceutical combination for the treatment of a cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013683A true MX2019013683A (es) | 2020-01-15 |
Family
ID=58765794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013683A MX2019013683A (es) | 2017-05-16 | 2018-05-15 | Una combinacion farmaceutica para el tratamiento de un cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11260042B2 (enExample) |
| EP (2) | EP4234035A3 (enExample) |
| JP (1) | JP7208650B2 (enExample) |
| KR (1) | KR102569052B1 (enExample) |
| CN (2) | CN110636842A (enExample) |
| AU (1) | AU2018269462B2 (enExample) |
| CA (1) | CA3063625A1 (enExample) |
| CL (1) | CL2019003288A1 (enExample) |
| ES (1) | ES2955524T3 (enExample) |
| HU (1) | HUE063275T2 (enExample) |
| IL (1) | IL270676B2 (enExample) |
| MX (1) | MX2019013683A (enExample) |
| PL (1) | PL3624786T3 (enExample) |
| WO (1) | WO2018210830A1 (enExample) |
| ZA (1) | ZA201907286B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018269462B2 (en) | 2017-05-16 | 2024-04-18 | Ability Pharmaceuticals S.L. | A pharmaceutical combination for the treatment of a cancer |
| IL295067A (en) | 2020-02-10 | 2022-09-01 | Ability Pharmaceuticals S L | Pharmaceutical combination for cancer treatment |
| CN120733048A (zh) * | 2025-08-29 | 2025-10-03 | 天津医科大学总医院 | 一种用于治疗肺鳞癌的药物组合物及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258816A (ja) * | 1987-04-16 | 1988-10-26 | Nippon Oil & Fats Co Ltd | 抗癌剤組成物 |
| CA2010511A1 (en) * | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| AU5928599A (en) * | 1999-09-09 | 2001-04-10 | Efa Sciences Llc. | Methods for treating cell proliferative disorders including cancer |
| GB0011903D0 (en) | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| RU2284818C2 (ru) | 2001-05-10 | 2006-10-10 | Анормед, Инк. | Комбинированная химиотерапия |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| KR101783817B1 (ko) | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| MY170185A (en) | 2011-10-18 | 2019-07-09 | Nestle Sa | Composition for use in brain growth and/or cognitive and/or psychomotor development |
| CN107050457A (zh) | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物 |
| AU2018269462B2 (en) * | 2017-05-16 | 2024-04-18 | Ability Pharmaceuticals S.L. | A pharmaceutical combination for the treatment of a cancer |
-
2018
- 2018-05-15 AU AU2018269462A patent/AU2018269462B2/en active Active
- 2018-05-15 WO PCT/EP2018/062554 patent/WO2018210830A1/en not_active Ceased
- 2018-05-15 EP EP23179349.8A patent/EP4234035A3/en active Pending
- 2018-05-15 MX MX2019013683A patent/MX2019013683A/es unknown
- 2018-05-15 EP EP18722621.2A patent/EP3624786B1/en active Active
- 2018-05-15 KR KR1020197034996A patent/KR102569052B1/ko active Active
- 2018-05-15 IL IL270676A patent/IL270676B2/en unknown
- 2018-05-15 US US16/614,084 patent/US11260042B2/en active Active
- 2018-05-15 JP JP2020514327A patent/JP7208650B2/ja active Active
- 2018-05-15 CN CN201880032629.0A patent/CN110636842A/zh active Pending
- 2018-05-15 CN CN202510115665.5A patent/CN119950727A/zh active Pending
- 2018-05-15 ES ES18722621T patent/ES2955524T3/es active Active
- 2018-05-15 HU HUE18722621A patent/HUE063275T2/hu unknown
- 2018-05-15 CA CA3063625A patent/CA3063625A1/en active Pending
- 2018-05-15 PL PL18722621.2T patent/PL3624786T3/pl unknown
-
2019
- 2019-11-01 ZA ZA2019/07286A patent/ZA201907286B/en unknown
- 2019-11-15 CL CL2019003288A patent/CL2019003288A1/es unknown
-
2022
- 2022-01-21 US US17/581,587 patent/US12053449B2/en active Active
-
2024
- 2024-07-03 US US18/763,671 patent/US12280033B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3624786C0 (en) | 2023-07-05 |
| US20220257554A1 (en) | 2022-08-18 |
| US20240350449A1 (en) | 2024-10-24 |
| RU2019135507A (ru) | 2021-06-16 |
| US20210154166A1 (en) | 2021-05-27 |
| AU2018269462A1 (en) | 2019-11-28 |
| EP4234035A2 (en) | 2023-08-30 |
| JP7208650B2 (ja) | 2023-01-19 |
| WO2018210830A1 (en) | 2018-11-22 |
| EP4234035A3 (en) | 2023-11-15 |
| KR102569052B1 (ko) | 2023-08-22 |
| EP3624786B1 (en) | 2023-07-05 |
| BR112019023944A2 (pt) | 2020-06-09 |
| CA3063625A1 (en) | 2018-11-22 |
| US11260042B2 (en) | 2022-03-01 |
| PL3624786T3 (pl) | 2023-10-30 |
| IL270676B1 (en) | 2024-07-01 |
| JP2020520385A (ja) | 2020-07-09 |
| IL270676B2 (en) | 2024-11-01 |
| US12053449B2 (en) | 2024-08-06 |
| EP3624786A1 (en) | 2020-03-25 |
| RU2019135507A3 (enExample) | 2021-09-03 |
| KR20200005573A (ko) | 2020-01-15 |
| CN119950727A (zh) | 2025-05-09 |
| AU2018269462B2 (en) | 2024-04-18 |
| IL270676A (enExample) | 2020-01-30 |
| CN110636842A (zh) | 2019-12-31 |
| ZA201907286B (en) | 2021-01-27 |
| US12280033B2 (en) | 2025-04-22 |
| ES2955524T3 (es) | 2023-12-04 |
| HUE063275T2 (hu) | 2024-01-28 |
| CL2019003288A1 (es) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201915522D0 (en) | Use of cannabidiol preparations in the treatment of absence epilepsy | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| GB201411465D0 (en) | Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer | |
| EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
| JOP20200231A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2023011202A (es) | Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds). | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| CA3292080A1 (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | |
| TW201713323A (en) | Therapeutic compositions and methods of use thereof | |
| MX2017013047A (es) | Tratamiento de dolor. | |
| HK1256174A1 (zh) | 用於治疗疼痛的 vap-1 抑制剂 | |
| EP4234035A3 (en) | A pharmaceutical combination for the treatment of a cancer | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| EP4268899A3 (en) | Ferritin nanoparticles comprising a chemotherapeutic agent | |
| IL271592B1 (en) | The compositions that combine an anti-inflammatory drug and the action of Dicer for the treatment of neurological diseases. | |
| HK40064163A (en) | Oligo-benzamide analogs and their use in cancer treatment | |
| HK40031514A (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |